Ling Bai, Zhang Zhengyu, Xiang Ze, Cai Yiqi, Zhang Xinyue, Wu Jian
Department of Pharmacy, The Yancheng Clinical College of Xuzhou Medical University, The First people's Hospital of Yancheng, Yancheng, China.
Nanjing Medical University School of Medicine, Nanjing, China.
Front Oncol. 2022 Sep 27;12:993781. doi: 10.3389/fonc.2022.993781. eCollection 2022.
Although the incidence and mortality of lung cancer have decreased significantly in the past decade, it is still one of the leading causes of death, which greatly impairs people's life and health. Proteomics is an emerging technology that involves the application of techniques for identifying and quantifying the overall proteins in cells, tissues and organisms, and can be combined with genomics, transcriptomics to form a multi-omics research model. By comparing the content of proteins between normal and tumor tissues, proteomics can be applied to different clinical aspects like diagnosis, treatment, and prognosis, especially the exploration of disease biomarkers and therapeutic targets. The applications of proteomics have promoted the research on lung cancer. To figure out potential applications of proteomics associated with lung cancer, we summarized the role of proteomics in studies about tumorigenesis, diagnosis, prognosis, treatment and resistance of lung cancer in this review, which will provide guidance for more rational application of proteomics and potential therapeutic strategies of lung cancer.
尽管在过去十年中肺癌的发病率和死亡率显著下降，但它仍然是主要的死亡原因之一，极大地损害了人们的生命和健康。蛋白质组学是一项新兴技术，涉及应用各种技术来识别和定量细胞、组织和生物体中的全部蛋白质，并且可以与基因组学、转录组学相结合形成多组学研究模式。通过比较正常组织和肿瘤组织之间蛋白质的含量，蛋白质组学可应用于诊断、治疗和预后等不同临床方面，尤其是疾病生物标志物和治疗靶点的探索。蛋白质组学的应用推动了肺癌研究。为了明确蛋白质组学在肺癌方面的潜在应用，我们在本综述中总结了蛋白质组学在肺癌发生、诊断、预后、治疗和耐药性研究中的作用，这将为蛋白质组学的更合理应用及肺癌潜在治疗策略提供指导。
